Abstract:Signaling through G protein coupled receptors (GPCRs) is highly regulated and shaped not only by how and when a GPCR engages its ligand, but also through complex and varied protein interactions at the level of the receptor and at downstream effectors. Opioid receptors are an excellent example of a GPCR system that is finely regulated in the central nervous system. The mu opioid receptor is the primary receptor that modulates acute pain responses and has been heavily targeted therapeutically for its anti‐nociceptive properties. The duration and extent of endogenous MOR signaling is modulated by available endogenous opioid peptides, by β‐arrrestin recruitment and subsequent receptor desensitization, by regulator of G protein signaling (RGS) control of Gαo activation, and by interaction with other GPCRs that may positively or negatively alter signaling. Using an unbiased forward genetic screen in MOR‐expressing c. elegans, we uncovered another possible regulator of MOR signaling: the orphan GPCR GPR139. Studies using GPR139 knockout mice demonstrate hypersensitivity to opioid analgesics across multiple measures of antinociception. However, the exact molecular mechanism(s) of how GPR139 activation and signaling can modulate MOR downstream signaling is unknown. We ran a battery of in vitro signaling assays to determine how GPR139 signals in cells and how that could negatively modulate MOR signaling. GPR139 G protein coupling was tested using every G alpha protein and was found to couple to both Gq/11 and Gi/o family of G proteins. We examined the effect of GPR139 on multiple parameters of MOR signaling and trafficking and found that GPR139‐Gq signals in an opposing manner to MOR‐Go signaling at multiple downstream effectors in vitro. Further, MOR‐mediated changes in habenular neuron firing are blunted by dynamic GPR139 activation and can be rescued by Gαq inhibition. Overall, this research examines the molecular underpinnings of GPR139 negative regulation of MOR, explores mechanisms of GPCR cross‐regulation, and evaluates the possibility of therapeutically targeting GPR139 to increase the safety and efficacy of opioids.

μ-Opioid Receptor Cell Surface Expression Is Regulated by Its Direct Interaction with Ribophorin I

N-glycosylation of the human neuropeptide QRFP receptor (QRFPR) is essential for ligand binding and receptor activation

Retromer Opposes Opioid-Induced Downregulation of the Mu Opioid Receptor

Cell surface targeting of μ-δ opioid receptor heterodimers by RTP4

GPR139 Signals Through Gq/11 to Oppose Mu Opioid Receptor Signaling

Phosphorylation State of Mu-Opioid Receptor Determines the Alternative Recycling of Receptor Via Rab4 or Rab11 Pathway

Opioid receptors reveal a discrete cellular mechanism of endosomal G protein activation

An engineered trafficking biosensor reveals a role for DNAJC13 in DOR downregulation

Structure of the µ-opioid receptor–G i protein complex

Profiling the proximal proteome of the activated μ-opioid receptor

17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-(4'-pyridylcarboxamido)morphinan (NAP) Modulating the Mu Opioid Receptor in a Biased Fashion.

[Nuclear factor A5 from the rat liver that requires a metal for specific interaction in vitro with distal element of the tyrosine aminotransferase gene promoter].

Computational Insights into the Molecular Mechanisms of Differentiated Allosteric Modulation at the Mu Opioid Receptor by Structurally Similar Bitopic Modulators

Molecular Characterization and Functional Expression of Opioid Receptor-Like1 Receptor

Functional differences in the mu opioid receptor SNP 118A>G are dependent on receptor splice-variant and agonist-specific recruitment of β-arrestin

In Vitro and in Vivo Functional Profile Characterization of 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3-carboxamido)morphinan (NAQ) As a Low Efficacy Mu Opioid Receptor Modulator.

Establishing the Framework to Evaluate Negative Modulators of Mu Opioid Receptor Signaling in Cells

Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.

Design and Synthesis of a Bivalent Ligand to Explore the Putative Heterodimerization of the Mu Opioid Receptor and the Chemokine Receptor CCR5.

Regulation of MOR‐1A, an Intron‐retention Splice Variant of the Mu Opioid Receptor (OPRM1) Gene, by Mir‐107

Homology modeling and molecular dynamics simulations of the mu opioid receptor in a membrane-aqueous system.